Cartalax vs Rigin

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

Cartalax is a Khavinson-class short bioregulator peptide investigated for connective tissue and cartilage maintenance. Like other ultrashort peptides in this research category, cartalax is proposed to reach musculoskeletal target cells via amino acid transporter mechanisms and influence gene expression pathways associated with cellular aging. Published preclinical studies of structurally related Khavinson peptides show regulation of aging-associated genes and epigenetic markers in mesenchymal stem cell models. Human clinical evidence specific to cartalax is limited; existing research is predominantly preclinical and based on related peptides within the same class. Cartalax benefits investigated in preclinical research include support for chondrocyte proliferation, extracellular matrix synthesis, and cartilage tissue homeostasis — areas relevant to age-related joint degeneration, osteoarthritis research, and connective tissue maintenance. As a bioregulator peptide, cartalax is proposed to work by modulating gene expression in cartilage-specific cells rather than providing direct structural repair, distinguishing it mechanistically from direct injections of growth factors or PRP. Research interest also extends to combined bioregulator protocols pairing cartalax with other Khavinson-class peptides targeting musculoskeletal and connective tissue health, including protocols used alongside cortagen for vascular-connective tissue support. Cartalax dosage: No human clinical trial has established a reference dose for cartalax. Preclinical research protocols in the Khavinson bioregulator literature have examined peptide bioregulators at doses in the microgram-to-low-milligram range via subcutaneous injection, typically administered in defined cycles. Oral bioregulator formulations of related Khavinson peptides have also been studied. Cartalax is a research compound with no approved human dosing guidelines.

Palmitoylated tetrapeptide mimicking IgG C-terminal sequence; reduces IL-6 production in keratinocytes; combined with Matrixyl (Pal-GHK) forms Matrixyl 3000; anti-inflammatory and skin matrix support

Rigin (Palmitoyl Tetrapeptide-7) is a synthetic cosmetic peptide developed to address skin inflammation and age-related matrix degradation. It is proposed to suppress interleukin-6 (IL-6), a cytokine associated with chronic low-grade skin inflammation that accelerates extracellular matrix breakdown. Evidence for rigin is primarily derived from manufacturer-sponsored in vitro and ex vivo cosmetic research; no independent peer-reviewed clinical trials have been identified in indexed biomedical literature. Rigin is a cosmetic ingredient developed by Sederma/Croda; its evidence base consists of manufacturer-sponsored studies only and it has not been evaluated by regulatory agencies for any medicinal claim. Rigin and Matrixyl 3000 Rigin (Palmitoyl Tetrapeptide-7, Pal-GQPR) is one of two peptide actives in Sederma's Matrixyl 3000 formulation — the other being Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS). In the Matrixyl 3000 combination, the two peptides are proposed to address complementary aspects of skin aging: Matrixyl (Pal-KTTKS) stimulates new collagen I and III synthesis via TGF-β signaling; Rigin (Pal-GQPR) suppresses IL-6-mediated matrix degradation, reducing the rate at which newly synthesised collagen is broken down. The combination therefore targets both the anabolic (synthesis) and anti-catabolic (degradation prevention) sides of collagen matrix maintenance. This mechanistic pairing is the basis for the "3000" formulation's improved efficacy claims relative to the original single-peptide Matrixyl. In cosmetic formulations, Rigin is listed under its INCI name (Palmitoyl Tetrapeptide-7) and appears alongside palmitoyl pentapeptide-4 in products marketed as containing Matrixyl 3000. Typical concentration in the final product is in the range of 4–8% of the Sederma Matrixyl 3000 concentrate, which itself contains the peptides at a defined dilution. Rigin is a topical cosmetic ingredient — it has no injectable or clinical pharmaceutical application and does not require a prescription in any jurisdiction.